Objectives: Reports of Enterobacteriaceae resistant to all commonly used antimicrobial agents, including b-lactams, fluoroquinolones and aminoglycosides, are increasing in hospitals worldwide. The activity of ACHN-490, a next-generation aminoglycoside, was examined against clinical isolates of Escherichia coli and Klebsiella pneumoniae from hospitals in New York City, an area where multidrug-resistant organisms are endemic.
Introduction
The emergence and rapid spread of multidrug-resistant Gramnegative pathogens in hospitals throughout the world has been alarming. The spread of Klebsiella pneumoniae possessing the carbapenemase KPC has been especially disconcerting. Originally confined to isolates in the north-eastern USA, KPC-producing isolates have now become commonplace in New York City and have been reported throughout North America and in Asia, South America and Europe. 1, 2 In addition, isolates of Escherichia coli carrying the KPC b-lactamase have also been identified in New York City. 3 Already resistant to b-lactam agents, many of the KPC-producing isolates are also resistant to fluoroquinolones and older aminoglycosides (for example gentamicin, tobramycin and amikacin), leaving only extremely limited therapeutic options. The urgent need for new antimicrobial agents has been highlighted by the recent "10×'20 initiative" by the Infectious Diseases Society of America. 4 ACHN-490 is a derivative of sisomicin with enhanced activity against many multidrug-resistant Gram-negative and Grampositive bacteria. 5 -8 Preliminary studies indicate bactericidal activity against several Gram-negative pathogens. 9 In this report, we determined the activity of ACHN-490 against contemporary clinical isolates of E. coli and K. pneumoniae from hospitals in New York City.
Materials and methods

Bacterial isolates
Single-patient isolates of E. coli and K. pneumoniae were gathered from hospital microbiology laboratories during a 3 month surveillance study Based on their various aminoglycoside MICs, a subset of isolates was selected for additional studies to investigate the potential mechanisms of resistance. Time-kill studies were performed on some of these isolates using 4× the MIC of ACHN-490 (MIC range 0.25 -4 mg/ L). 9 Bactericidal activity was defined as a ≥3 log drop in the inoculum after 24 h of incubation. 11 For some isolates, MICs were repeated by the broth microdilution method with and without the presence of the efflux pump inhibitors 1-(1-naphthmethyl)-piperazine (NMP) and phenyl-arginine-b-naphthylamide (PABN). 12 NMP was included at 200 mg/L (0.5× the MIC for the tested isolates). PABN was included at 100 mg/L, representing 0.5× to 0.0625× the MIC for the tested isolates.
PCR studies
For a subset of isolates, the presence of genes encoding aminoglycosidemodifying enzymes was determined by PCR using previously reported primers and conditions. 13, 14 The following genes were screened:
; and aac(3)-IIa (aacC2). Genes encoding aminoglycoside-modifying enzymes were also detected by amplifying and sequencing class 1 integrons using primers derived from the 5 ′ and 3 ′ conserved segments. 15 PCR amplicons of integrons were cloned into pCR2.1 TOPO with One Shot TOP10 E. coli (Invitrogen, Carlsbad, CA, USA) and identified by bidirectional DNA sequencing. Isolates with highlevel resistance (.32 mg/L) to all three aminoglycosides were screened for the presence of genes encoding 16S rRNA methylases (armA, rmtA, rmtB, rmtC and rmtD) by PCR using previously identified primers. 16 -19 Additionally, for these isolates, the presence of the following modifying enzymes was determined using the designated primers (5 ′ -3 ′ ): aac(3)-IIIa, forward GACTTTATCGACTCGCTGCC and reverse AACAGGTAAG CATCCGCATC; and aac(3)-Vb, forward CCCTATGAGGAGACGCTGAA and reverse GAGACGATATCCTGCGCTTC. Finally, the presence of bla KPC was screened by PCR using previously identified primers and conditions. 20 The following integron sequences have been deposited in GenBank: GU358475 (E. coli ME451); GU358476 (K. pneumoniae KB20); and GU35 8477 (K. pneumoniae KB18).
Results
E. coli
A total of 3050 isolates of E. coli were collected during the surveillance study involving the 16 hospitals (Table 1) . Although most were susceptible to the three aminoglycosides, the MIC 90 values for gentamicin, tobramycin and amikacin were 32, 8 and 4 mg/L, respectively. Only three isolates (0.1%) had MICs of ACHN-490 ≥8 mg/L; two were obtained from urine cultures and one was from a blood culture. A subset of 36 isolates, including one with bla KPC , was selected based on the MICs of gentamicin, tobramycin, amikacin and ACHN-490 (Table 2) . Among these isolates, 61% were resistant to ciprofloxacin and 44% to trimethoprim/sulfamethoxazole, and 56% had a ceftazidime MIC .1 mg/L. Isolates were grouped according to the aminoglycoside-modifying enzymes genes that were detected. Time-kill studies were conducted with nine isolates with concentrations of ACHN-490 at 4× MIC ( Table 2) . Bactericidal killing was evident in seven isolates. Two isolates, possessing aac(3)-IIa and an integron-associated aadA5, had evidence of regrowth at 24 h. Insertion of the integron carrying aadA5 into a susceptible TOP10 E. coli did not change the MIC of ACHN-490 (0.25 mg/L) when compared with a TOP10 isolate without this enzyme. For the two isolates exhibiting regrowth, the isolates recovered after 24 h of incubation had an 8-to 16-fold increase in the MIC of ACHN-490. The addition of the efflux inhibitor NMP had no effect on the ACHN-490 MICs, and the addition of PABN caused a 4-fold decrease in one isolate. Only one of the two isolates exhibiting regrowth had a 4-fold rise in the MICs of gentamicin, tobramycin and amikacin.
K. pneumoniae
During the surveillance study, 1155 isolates of K. pneumoniae were gathered. Although resistance to the aminoglycosides was common (Table 3) , only two isolates (0.2%) had ACHN-490 MICs ≥8 mg/L. It is noteworthy that, although the two isolates originated from two separate hospitals, they belonged to the same ribotype (data not shown). Among the surveillance isolates with bla KPC , the ACHN-490 MIC 50 and MIC 90 were unchanged at 0.5 and 1 mg/L, respectively. Forty isolates (including 25 multidrug-resistant isolates with bla KPC ) were chosen for further analysis based on their range of MICs of the aminoglycosides (Table 4) . Among these isolates, 80% were resistant to ciprofloxacin and 88% to trimethoprim/sulfamethoxazole, and 83% possessed extended-spectrum b-lactamases. As with the 
Discussion
The emergence of multidrug-resistant Gram-negative nosocomial pathogens has created serious therapeutic challenges. In New York City, 22% of K. pneumoniae isolates are resistant to all commonly used antimicrobial agents, 1 and carbapenem-resistant isolates of E. coli have been reported. 3 Resistance to aminoglycosides is also common, particularly among K. pneumoniae, due to the acquisition of several aminoglycoside-modifying enzymes.
Resistance to tigecycline and polymyxin B has also been noted in 5% of isolates of K. pneumoniae. 1 The development of new agents is sorely needed.
ACHN-490, a derivative of sisomicin, possesses activity against a broad range of Enterobacteriaceae, with MIC 90 values of 1 -2 mg/L. 5 -8 The activity of ACHN-490 is retained against most aminoglycoside-resistant isolates, including multidrugresistant KPC-producing strains. ACHN-490 MICs do not seem to correlate with commonly found aminoglycoside-modifying enzymes. Although isolates in our study with increased ACHN-490 MICs were found to carry AAC(6 ′ )-Ib, this enzyme was also found in more susceptible strains. It is likely that the presence of a hydroxymethyl group at the 6 ′ position may stabilize this site against AAC(6 ′ )-Ib enzymes, and the occurrence of the enzyme in these isolates reflects its high prevalence in clinical isolates rather than any effect on ACHN-490 activity. Bactericidal activity is evident at concentrations 4× the MIC for most strains. However, regrowth has been found upon exposure to either ACHN-490 or traditional aminoglycosides in occasional isolates at this concentration. 9 The mechanisms behind elevated MICs of ACHN-490 remain unclear. In Acinetobacter baumannii, increased expression of the efflux system AdeB may correlate with reduced susceptibility to ACHN-490. 7 Although not encountered in this study, the presence of ribosomal methylases may affect susceptibility to this agent. 8 Additional investigations involving Enterobacteriaceae, particularly studies examining the roles of efflux systems, ribosomal alterations and changes in outer membrane permeability, will be needed. Based on our in vitro results, ACHN-490 is a potentially useful therapeutic agent against multidrug-resistant E. coli and K. pneumoniae, including KPC-producing strains.
